Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Effect of Kidney Yang Deficiency Syndrome on Testis Tissue in Rats

PROVIDER: PRJNA743645 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15037572_1.fastq.gz	Fastqsanger.gz
	SRR15037572_2.fastq.gz	Fastqsanger.gz
	SRR15037573_1.fastq.gz	Fastqsanger.gz
	SRR15037573_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Project description:Effect of Kidney Yang Deficiency Syndrome on Kidney Tissue in Rats

| PRJNA733813 | ENA

Project description:Effect of Kidney Yang Deficiency Syndrome on Bone Tissue in Rats

| PRJNA734479 | ENA

Project description:Effect of Kidney Yang Deficiency Syndrome on Cartilage Tissue in Rats

| PRJNA734523 | ENA

Project description:Effect of Kidney Yang Deficiency Syndrome on Thyroid Tissue in Rats

| PRJNA743922 | ENA

Project description:Effect of Kidney Yang Deficiency Syndrome on Adrenal Gland Tissue in Rats

| PRJNA743336 | ENA

Multi-group analysis of TCM syndrome types of patients with colorectal cancer

Project description:Interventions: Patients with spleen deficiency and qi stagnation syndrome SDQSS:NA;Patients with DHS with damp-heat accumulation syndrome:NA;Patients with SPOS with stasis and internal resistance syndrome:NA;Patients with SKYDS of Spleen and Kidney Yang Deficiency Syndrome:NA;Patients with liver-kidney yin deficiency syndrome LKYDS:NA;QBDS patients with deficiency of both qi and blood syndrome:NA Primary outcome(s): Serum metabolites;Fecal microbiome;lipidomics Study Design: Diagnostic test for accuracy

| 105810 | ecrin-mdr-crc

Genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency

Project description:Investigate genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency in peripheral blood By TCM syndrome, 10 patients with postmenopausal osteoporosis were divided into three groups: kidney Yin deficiency (n=4), kidney Yang deficiency (n=3), non-kidney deficiency (n=3), another 3 healthy postmenopausal women also were selected as control group. Whole human genome oligo microarray were applied to explore gene expression difference of the groups. Kidney Yin deficiency group was compared with other three groups respectively.

2014-03-23 | E-GEOD-56116 | biostudies-arrayexpress

Proteomic analysis of Fuzi and its processed products in treating Yang Deficiency Rats

Project description:The model rats of Yang deficiency syndrome were established by gavage of Huanglian and Dahuang and exhaustive swimming. The rats were treated with Fuzi, Yinfupian and Yangfupian. The liver tissue proteins were extracted and analyzed by TMT proteomics.

2021-05-27 | PXD026321 |

Profiling alterations of the metabolomic and transcriptomic characteristics and the therapeutic mechanism of Psoraleae Fructus in treating kidney-yang deficiency syndrome rats

Project description:Kidney-yang deficiency syndrome (KYDS) is a metabolic disease caused by neuroendocrine disorders often accompanied by abnormal liver function. Psoraleae Fructus (BGZ) is widely used to treat KYDS in China, but it is unclear whether BGZ plays a therapeutic role in regulating liver function. Organ index, ALT, AST, and HE staining were used to evaluate the protective effect of BGZ on KYDS in rats, and transcriptomics and metabolomics were employed to screen for potential biomarkers. The results showed that BGZ treatment significantly decreased the levels of ALT and AST, and ameliorated liver pathological damage in KYDS rats. 92 differentially expressed genes (DEGs) and 20 metabolites were significantly disturbed by BGZ in KYDS rats. Integrated analysis of metabolites and DEGs revealed that neuroactive ligand-receptor interaction, cAMP pathway, calcium signaling pathway, and cytokine-cytokine receptor interaction may be the main mechanism of BGZ treatment, and the key targets of the cAMP pathway were confirmed by ELISA and RT-qPCR. In conclusion, the cAMP pathway may be the partial mechanism by which BGZ exerts protective effects on KYDS, and the study results also lay the foundation for more in-depth mechanistic studies and drug-targeted therapy of KYDS in the future.

2023-12-31 | GSE249348 | GEO

Tissue-specific response of microRNAs to carcinogenicity and mutagenicity of aristolochic acid in rats

Project description:Aristolochic acid (AA) is an active component of herbal drugs derived from the Aristolochia species that have been used for medicinal purposes since antiquity. However, AA is genotoxic and induces tumors in animals and humans. AA induces mutations and tumors in the kidney but solely mutations in the liver. To evaluate whether miRNAs could indicate AA’s tissue-specific carcinogenicity and mutagenicity, we first conducted microarray analysis of miRNA expression in kidneys and livers of rats treated with a carcinogenic dose of AA. Then, miR-21, a biomarker for carcinogenicity, and miR-34a, a biomarker for mutagenicity, the two miRNAs whose expressions were most altered, were evaluated for their expression in the kidney (the AA’s mutagenic and carcinogenic target tissue), liver (the AA’s mutagenic target tissue), and testis, the non-target tissue where neither tumors nor mutation induction was found in previous studies and in this study. Genomic analysis of miRNA expression for kidney and liver samples showed that miRNA expression was globally changed by the treatment. Nineteen miRNAs were significantly dysregulated by the treatment in the kidney. Most of these miRNAs are related to carcinogenesis. Only one miRNA, miR-34a, was differentially expressed in the liver. Expression of miR-21 was induced in the kidney by AA treatment in a dose-dependent manner while no changes occurred in the liver or testis, indicating that the kidney is the carcinogenic target. miR-34a was dose-dependently up-regulated in the kidneys and livers of rats treated with AA, but not in the testis, suggesting that the kidney and liver are mutagenic target tissues, but the testis is not. Our results demonstrate that miRNA profiles can reflect the AA’s carcinogenicity in a tissue-specific manner while specific miRNAs can signify the target tissues for carcinogenicity or mutagenicity of AA.

2013-11-10 | GSE50946 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data